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Achieving Quality in Cardiovascular Imaging November 21, 2006:2141–51BSTRACT
ardiovascular imaging has enjoyed both rapid technolog-
cal advances and sustained growth, yet less attention has
een focused on quality than in other areas of cardiovascular
edicine. To address this deficit, representatives from
ardiovascular imaging societies, private payers, government
gencies, the medical imaging industry, and experts in
uality measurement met, and this report provides an
verview of the discussions. A consensus definition of
uality in imaging and a convergence of opinion on quality
easures across imaging modalities was achieved and are
ntended to be the start of a process culminating in the
evelopment, dissemination, and adoption of quality mea-
ures for all cardiovascular imaging modalities.
NTRODUCTION
maging has transformed cardiovascular medicine by im-
roving the prevention, diagnosis, and management of
ardiovascular disease. The sustained growth of imaging
hows the central role that imaging plays in the care of
atients with known or suspected cardiovascular disease.
nsuring a high level of quality has now become an
mportant focus for patients, physicians, and payers because
f advances in existing imaging technologies and the emer-
ence of new modalities.
Quality of care has been defined by the Institute of
edicine as “the degree to which health care systems,
ervices, and supplies for individuals and populations in-
rease the likelihood for desired health outcomes in a
anner consistent with current professional knowledge” (1).
everal initiatives to improve quality for patients with
ardiovascular conditions have been implemented (2,3).
owever, these programs have predominately focused on
valuating the use of evidence-based therapies (4,5), and
uality in imaging has been relatively hidden from view.
lthough few studies have shown marked geographic vari-
tion in imaging use (6,7), there is little information about
here quality gaps exist and how they ultimately affect
atient care and outcomes.
To respond to this need, the American College of
ardiology (ACC) and Duke University convened a meet-
Abbreviations and Acronyms
ACC  American College of Cardiology
ACR  American College of Radiology
ASE  American Society of Echocardiography
ASNC  American Society of Nuclear Cardiology
COCATS  Core Cardiology Training Symposium
CT  computed tomography
JCAHO  Joint Commission on the Accreditation of
Healthcare Organizations
MR  magnetic resonance
SPECT  single-photon emission computed
tomographyng of representatives of cardiovascular imaging societies,rivate payers, government agencies, industry, and experts
n quality measurement in January 2006. This report pro-
ides a review of the discussions and proposes efforts to
stablish quality standards for cardiovascular diagnostic
maging, beginning with an emphasis on valid quality
easurement tools. The meeting achieved a consensus defini-
ion of quality in imaging and a convergence of opinion toward
he development and dissemination of quality measures for
ach imaging modality within 18 months.
RINCIPLES OF QUALITY MEASUREMENT
he conference embraced Donabedian’s (8) methodology of
uality assessment by applying his structure-process-
utcome model to cardiovascular imaging. Structure repre-
ents the infrastructure through which care is delivered,
uch as equipment, staff training, and laboratory protocols.
rocess refers to those actions performed in delivering care to
atients, and includes such concepts as patient selection,
mage acquisition, interpretation, and reporting. Outcomes
re the events that occur as a result of the impact of imaging
n clinical decision making, and they can encompass mor-
ality, morbidity, quality of life, cost, and satisfaction.
erformance measures are the discrete parameters of struc-
ure, process, or outcome whose attainment defines good
uality care.
Currently, quality assessment of cardiac imaging labora-
ories primarily occurs through voluntary accreditation
hrough the Intersocietal Accreditation Commission and its
elevant agencies (Table 1). The American College of
adiology (ACR) also provides accreditation for vascular
ltrasound (9) and nuclear cardiology (10) laboratories, and
s developing accreditation processes for cardiac magnetic
esonance (MR) and cardiac computed tomography (CT)
maging. The Joint Commission on the Accreditation of
ealthcare Organizations (JCAHO) provides an implicit
ccreditation of a facility that has a cardiac catheterization
aboratory. By remedying inconsistent adherence to pub-
ished standards and guidelines, accreditation can ensure an
bjective baseline level of care and provide a mechanism for
mplementing quality improvement initiatives. The ACC,
he American Society of Nuclear Cardiology (ASNC), the
merican Society of Echocardiography (ASE), the Society
or Vascular Medicine and Biology, and the ACR strongly
upport accreditation of echocardiography, vascular ultra-
ound, and nuclear cardiology laboratories (11,12).
able 1. Intersocietal Commission for Accreditation Members
Intersocietal Commission for Accreditation of Vascular Laboratories
(ICAVL) (33)
Intersocietal Commission for Accreditation of Nuclear Laboratories
(ICANL) (36)
Intersocietal Commission for Accreditation of Echocardiographic
Laboratories (ICAEL) (46)
Intersocietal Commission for Accreditation of Magnetic Resonance
Laboratories (ICAMRL)
Intersocietal Commission for Accreditation of Cardiac Computed
Tomography Laboratories (ICACCTL)—under development
n
o
i
p
t
w
m
d
f
s
r
c
a
q
o
a
Q
A
i
s
A
m
t
m
d
s
s
e
a
i
T
p
e
m
p
w
p
q
a
r
r
t
i
t
c
s
or eva
T
L
P
I
I
R
I
2143JACC Vol. 48, No. 10, 2006 Douglas et al.
November 21, 2006:2141–51 Achieving Quality in Cardiovascular ImagingHowever, quality measurements beyond accreditation are
eeded for the following reasons: 1) accreditation identifies
utliers who fall below baseline standards but provides less
nformation on the quality of care delivered by typical
erformers who treat the majority of patients; 2) accredita-
ion typically describes conditions during a snapshot in time,
hereas ongoing monitoring for continued quality improve-
ent is more desirable; and 3) the value of accreditation
epends on the appropriateness of the accreditation criteria;
or example, some accrediting bodies allow laboratories to
elect what will be reviewed, which may provide an unrep-
esentative assessment. Thus, the conference participants
oncluded that ongoing quality monitoring would be valu-
ble even in accredited facilities, and should include novel
uality indicators based on clear clinical evidence, validated
n suitable patient populations, and amenable to appropri-
te standardization and risk adjustment.
UALITY MEASUREMENT IN IMAGING
taxonomy and model for evaluating cardiovascular
maging. The conference participants used methods de-
cribed in recent reviews on creating quality measures (13).
n initial step in creating quality measures is to define a
odel of the dimensions of care that defines a taxonomy for
he imaging process and identifies areas for quality improve-
Figure 1. Dimensions of care framework f
able 2. Quality Goals and Action Items in the “Dimensions of
Quality Goals
aboratory structure Ensure baseline standards for equipment
and staff proficiency
atient selection Appropriateness
mage acquisition Diagnostic quality images
Patient safety
mage interpretation Reproducibility
Accuracy
esults communication Interpretability
Clarity
Definitiveness
Completeness
Timeliness
mproved patient care
(outcomes)
Satisfaction
Impact on clinical management
Morbidity
Mortalityent (Fig. 1). The proposed model consists of 4 distinct
omains of process that affect clinical outcome: patient
election, image acquisition, image interpretation, and re-
ults communication. Elements of laboratory structure (e.g.,
quipment, staffing, protocols, and infrastructure) influence
nd support the 4 process domains.
The process begins with the referral for a cardiovascular
maging procedure to address one or multiple indications.
he first phase of assessing quality is to ensure appropriate
atient selection for a particular study on the basis of
vidence or consensus that it is reasonable, will affect
edical decision making, and will lead to quantifiable
atient benefits. Next is the acquisition of images using
ell-functioning equipment, proficient laboratory staff, and
rotocols that safely and reproducibly obtain diagnostic-
uality images optimized for individual patients. The im-
ges are then interpreted with goals of high accuracy and
eproducibility. Finally, test results must be communicated to
eferring physicians in a complete, clear, clinically relevant, and
imely manner to optimize patient treatment and ultimately
mprove health outcomes.
Quality measures should be developed for each step in
his conceptual framework. General concepts of cardiovas-
ular imaging quality and potential action plan items are
ummarized in Table 2. Because certain quality elements are
luating quality of cardiovascular imaging.
” Framework for Cardiovascular Imaging
Action Items
Mandate laboratory accreditation
Develop physician training and certification requirements
Support technologist certification
Develop additional laboratory accreditation processes for all modalities
Develop appropriateness criteria for all imaging modalities
Define key acquisition elements of imaging protocols and sequences
Develop standard methods for determining inter-reader and
intrareader variability
Develop timeliness criteria
Develop standards for completeness and definitiveness
Define key structured reporting data elements
Create structured reports for all modalities
Develop standard methods for determining cross-modality correlation
Develop methods for measuring patient outcomes and impact on
medical decision makingCare
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Achieving Quality in Cardiovascular Imaging November 21, 2006:2141–51ore relevant to particular modalities, a discussion of
odality-specific quality issues follows in the text and in
able 3.
uality in the dimensions of care for cardiovascular
maging. PATIENT SELECTION. The growth and costs of
ardiovascular imaging have focused attention on how these
ests are used (14). The goal of patient selection is to
dentify patients who would benefit from each imaging
odality while minimizing inappropriate testing and opti-
izing the opportunity for imaging to define therapeutic
trategies that improve patient outcomes. Simply stated,
uality in patient selection means referring the right patient
or the right test at the right time.
Appropriateness criteria can be a guide to whether an
maging procedure is a “reasonable” approach for a given
linical circumstance. In 2005, the ACC established the
ppropriateness Criteria Working Group to describe indi-
ations for which imaging procedures may be considered
ppropriate for generating information that has positive
onsequences for a patient’s care (15). Although many
cceptable indications outside of these appropriateness cri-
eria exist, measuring the degree of adherence to the clinical
ituations covered by such criteria would be valuable for
ssessing quality of patient selection. The ACR also devel-
ped appropriateness criteria for a variety of indications,
ncluding chest pain, but used a different approach (16).
The conference emphasized the importance of developing
ppropriateness criteria for each modality. Appropriateness
riteria for myocardial perfusion imaging were recently
ublished (17) with criteria for other modalities under
evelopment. The ACC and the American Heart Associa-
ion in conjunction with Society for Cardiovascular Angiog-
aphy and Interventions have published guidelines for cor-
nary angiography that could serve as a foundation for
ppropriateness criteria (18).
One challenge in evaluating appropriateness is the limited
atient information available to the imaging laboratory. Al-
hough the physician who supervises and interprets the study is
ltimately responsible for quality, the imaging test is often
erformed solely in response to the referring physician’s request
ithout engaging the imaging specialist as a consultant. Edu-
ational efforts must also include providing ordering health care
roviders with the latest data regarding test performance and
alue for clinical applications.
Devising and implementing measures of appropriateness
ill require time-efficient methods of data collection of
tudy indications and relevant clinical history. The consen-
us was that this clinical information should be provided by
he referring provider to the imaging laboratory. As a first
tep, the conference participants recommended that the
CC and relevant imaging societies develop standardized
nformation about test indications to provide feedback to
eferring providers about their test ordering behavior. Al-
hough more work is needed, optimizing patient selection is
mportant because it impacts on downstream testing, pro-
edures, and costs (19). tMAGE ACQUISITION. High-quality image acquisition de-
ends on modality-specific processes, including specific
rotocols and sequences that optimize the likelihood that
mages are of sufficient diagnostic quality. Adherence to
uch laboratory protocols could be a potential means of
valuating quality. Modality-specific quality measures may
nclude quantifying causes of inadequate studies (e.g., ex-
essive patient motion, lack of adequate contrast utilization,
nd so on), and use of “standard” modality-specific tech-
iques (e.g., dose modulation for cardiac CT, gated single-
hoton emission computed tomography [SPECT] for nu-
lear cardiology, and so on). The availability and expertise of
edical physicists are also important for optimizing image
uality. Factors related to patient and staff safety such as
adiation training and dosages, limiting use of potentially
ephrotoxic contrast agents, and avoidance of metallic
bjects within a magnetic field can provide measurements of
cquisition safety.
Accuracy and reproducibility can be evaluated with the
se of standard phantoms. For example, a standard phan-
om for cardiac catheterization laboratories is available to
ssess image quality and radiation dosimetry (20). Alterna-
ively, serial examinations or standardized patients may be
sed to assess ultrasound, nuclear cardiology, or cardiovas-
ular (CMR) studies.
The skills, training, and certification of technologists who
perate imaging equipment are also important consider-
tions. Cardiovascular-specific specialty credentialing is
vailable and encouraged for echocardiography (21) and
uclear medicine (www.nmtcb.org). There are also ad-
anced certifications for technologists in MR and CT and
ascular ultrasound. The percentage of studies performed by
echnologists with advanced credentials in imaging is a
otential example of a quality measure of staff proficiency.
MAGE INTERPRETATION. The training and expertise of
hysician readers are important standards for assessing the
uality of image interpretation. Guidelines for physician
raining for each modality have been described by the
CC’s Core Cardiology Training Symposium (COCATS)
22). Clinical competence statements have also been pub-
ished recently for cardiac CT and MR imaging by the ACC
nd the ACR (23,24) and already exist for echocardiography
25), stress echocardiography (26), and nuclear cardiology
26). In addition, specialized examinations of physician
roficiency are available in nuclear cardiology (Certification
oard of Nuclear Cardiology, www.cbnc.org), echocardiogra-
hy (National Board of Echocardiography, www.echoboards.
rg), and vascular ultrasound (American Registry for Diag-
ostic Medical Sonography, www.ardms.org).
However, high-quality imaging interpretation cannot be
uaranteed simply by the certification of an imaging spe-
ialist. Providing objective evidence of accuracy and repro-
ucibility should be a major component of quality in cardiac
maging. Mechanisms to assess accuracy include comparing
he results from one study with those from a different
Table 3. Examples of Quality Measures and Action Items Proposed by the Cardiovascular Imaging Modality Working Groups
Echocardiography Vascular Ultrasound Nuclear Cardiology Cardiac CT Cardiac MR Diagnostic Angiography
Laboratory structure ● Laboratory accreditation
(ICAEL)
● % labs accredited*
● % of studies by credentialed
sonographers*
● % of sonographers with
advanced credentialing*
● Interpreters with  COCATS
Level II training (tracking
those with NBE certification)*
● Laboratory accreditation
(ICAVL, ACR)*
● Laboratory accreditation
(ICANL, ACR)
● % with laboratory accreditation
● % of studies interpreted by CBNC-
certified physicians
● Develop accreditation
standards* (ICACCTL,
ACR)
● Laboratory accreditation
(ICAMRL, ACR)
● % of MR technologists with
advanced credentialing
● Laboratory accreditation
(JCAHO)*
Patient selection ● Develop appropriateness
criteria*
● % studies meeting
appropriateness criteria
● Appropriateness criteria
● Track indications of
normal studies
● Appropriateness criteria
● Develop instrument to evaluate
appropriateness*
● % studies meeting appropriateness
criteria*
● Appropriateness criteria
● Develop instrument to
evaluate appropriateness*
● % studies meeting
appropriateness criteria
● Appropriateness criteria
● % studies with indication
recorded*
● Develop instrument to evaluate
appropriateness*
Image acquisition ● Define minimum criteria for
examination elements*
● Formalize guidelines for use
of contrast*
● % studies performed with
contrast
● % studies uninterpretable*
● Repeat studies for
reproducibility
● Compliance with existing imaging
standards
● % of nondiagnostic studies
● Recording of corrective actions
● Develop standard
protocols*
● % complete studies
● % studies uninterpretable
● % studies using dose
modulation
● % studies with incidental
findings
● Develop standard protocols*
● % studies uninterpretable*
● Measure radiation dose
● Annual radiation safety training
● Contrast volume
● Quarterly image quality
assessment
● Weekly conferences
Image interpretation ● Inter-reader and intrareader
variability
● Internet-based standard image
set*
● Ongoing quality improvement
● 5% or 50 studies reviewed
● Physician interpretation
examination
● Inter-reader and intrareader variability*
● Internet-based standard image set
● Evaluation of serial testing for
variability
● Time to reading high-risk findings
● 5% overread with
examination of variability
● Internet-based standard
image set
● Concordance with
catheterization
● Inter-reader and intrareader
variability
Results communication ● Define key report data
elements*
● Develop timeliness guidelines
for reports
● % studies with critical
parameters (e.g., LVEF)
● Define key report data
elements
● Define timeliness
guidelines for reports
● Define key report data elements
● Develop timeliness guidelines for
reports
● % reports with complete data
● 90% definitely reported as normal or
abnormal*
● Define key report data
elements*
● Define key report data
elements
● Develop timeliness guidelines
for reports
● Develop clarity guidelines
● Define key report data
elements
Improved patient care
(outcomes)
● Correlation with other
modalities*
● Cost effectiveness
● Correlation with other
modalities*
● Correlation with other modalities
● Rate of coronary angiography without
CAD after abnormal perfusion study
● Rate of coronary
angiography without
CAD after abnormal CT
angiogram*
● Correlation with other
modalities
● % uninterpretable studies
● Patient and physician
satisfaction survey
● Normal coronary angiography
rates*
● Data collection via ACC
CathKit, NCDR*
Completed items in bold. *Highest priority items.
ACR  American College of Radiology; CAD  coronary artery disease; CBNC  Certification Board of Nuclear Cardiology; COCATS  Core Cardiology Training Symposium; CT  computed tomography; ICACCTL 
Intersocietal Commission for Accreditation of Cardiac Computed Tomography Laboratories; ICAEL  Intersocietal Commission for Accreditation of Echocardiographic Laboratories; ICAMRL  Intersocietal Commission for
Accreditation of Magnetic Resonance Laboratories; ICANL  Intersocietal Commission for Accreditation of Nuclear Laboratories; ICAVL  Intersocietal Commission for Accreditation of Vascular Laboratories; JCAHO  Joint
Commission on the Accreditation of Healthcare Organizations; LVEF  left ventricular ejection fraction; MR  magnetic resonance; NBE  National Board of Echocardiography; NCDR  National Cardiovascular Data Registry.
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Achieving Quality in Cardiovascular Imaging November 21, 2006:2141–51maging modality through periodic clinical conferences or
nalysis of computerized databases (27). Reproducibility can
e quantified by measuring intrareader and interreader
ariation by selecting, on a regular basis, a master set of cases
or review by each reader within a laboratory. Further
valuation could include a periodic external review of a set of
tudies by a core laboratory or other external reviewers. A
tandard set of images for common diagnoses could be
reated to calibrate interpretations and thereby reduce
ariability. Even the comparison of an older examination to
he current study may serve as means of determining
eproducibility. The effect of adding computerized quanti-
ation to subjective interpretation to reduce variation and
mprove accuracy should be explored. Regardless of the
pproach taken, it is critical that some form of ongoing
easurement of accuracy and reproducibility be performed
outinely, and that reasonable standards for both are
mplemented.
ESULTS COMMUNICATION. Reporting unambiguous con-
lusions and developing image reporting standards are
ritical opportunities to ensure high-quality reports that are
omplete and easily interpreted by referring physicians.
tandardized report formats have been published for echo-
ardiography (28) and nuclear cardiology (29), although
urther delineation of report content is necessary because
uture electronic medical records will contain uniform struc-
ured data fields that span many modalities. The 17-
egment model for left ventricular function is an example of
ollaboration between various cardiovascular imaging mo-
alities to develop a common language (30). Each modality
hould identify the minimal set of data elements that
ompose a high-quality report. The ASNC has recently
efined data elements to be used by nuclear cardiology
eports with the goal of creating a uniform national database
31). Once structured reporting is in place, measures of
uality can be developed such as the percentage of reports
hat contain specific data (e.g., ejection fraction in studies
or which that measure is appropriate); the percentage that
re “complete,” containing all required data elements; or the
roportion of reports with definitive conclusions rather than
ndeterminate results.
Imaging results must be communicated in a clear and
imely fashion, and devising objective measures of timely
eporting was encouraged. High-risk imaging findings must
rompt the rapid notification of the ordering physician.
imeliness standards should be developed that are specific
o the clinical situation and imaging modality. Finally,
eveloping reporting mechanisms that assist referring pro-
iders by indicating the significance of particular findings
ay prove valuable.
MPROVED PATIENT CARE AND CLINICAL OUTCOMES. Ap-
ropriate, high-quality imaging leads to improved decision
aking and patient care. However, clinical outcomes them-
elves did not emerge as a feasible initial quality measure.
lthough imaging provides abundant information regarding iiagnosis and risk stratification, few randomized clinical
tudies have examined its effect on clinical decision making
r patient outcomes; this is a fertile area for further research.
eferring physician satisfaction is an indirect outcome but
ne that could be measured. Other potential measures
nclude the rate of false-positive findings after comparison
ith a gold standard, or examining the rate of false-negative
esults that subsequently led to undesirable patient
utcomes.
UALITY MEASUREMENT BY
ARDIOVASCULAR IMAGING MODALITY
lthough many cross-modality quality themes were identi-
ed, each imaging modality had its own prioritization of
uality measures during the conference (Table 2). These
roposals are preliminary and need to be confirmed by each
maging society, but they represent early efforts for quality
easurement development, as well as the consensus of
onference participants.
chocardiography. The ASE recommends mandatory
aboratory accreditation through Intersocietal Commission
or Accreditation of Echocardiographic Laboratories as a
equirement for reimbursement (11), recommends image
cquisition by credentialed sonographers and interpretation
y physicians with at least COCATS level II training
11,32), and supports physician certification by the Examina-
ion of Special Competence in Adult Echocardiography from
he National Board of Echocardiography (www.echoboards.
rg). Appropriateness criteria are in development by an
CC Foundation Working Group with participation by
SE. The ASE will assist in defining key elements of image
cquisition (scan protocol), including appropriate rates of
ontrast use for left ventricular opacification. Development
f data elements and structured reporting standards are
ecessary, as well as identifying items critical for inclusion in
ll reports (e.g., left ventricular ejection fraction). Recom-
endations for the timeliness of reports will be generated.
roposed interpretation quality measures include the use of
eb-based case studies to assess variation of interpretation
nd for comparison against a national gold standard. The
cho Tool Kit under development by the ASE may be a
aluable tool for quality measurement and improvement.
ascular ultrasound. Vascular laboratories must be ac-
redited by Intersocietal Commission for Accreditation of
ascular Laboratories (ICAVL) (33) or the ACR (9) in
ost states to be eligible for reimbursement. A consensus
ocument on clinical competence in vascular medicine has
een published (34), and a vascular interpretation examina-
ion was recently initiated for physician credentialing
www.ardms.org/examinations/pvi.htm). The appropri-
te indications for vascular studies will be reviewed
hortly (35). The working group recommended tracking
he number of normal studies by referring physician, the
ate of uninterpretable/non-diagnostic studies, and repeat-
ng a percentage of studies to determine reproducibility.
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November 21, 2006:2141–51 Achieving Quality in Cardiovascular Imagingetrics that define an adequate study need to be developed.
he key data elements for a vascular laboratory report are
efined by ICAVL (www.intersocietal.org/icavl/apply/
tandards.htm). Also recommended are internal and exter-
al review processes, including review of the lesser of 5% or
0 studies annually to establish intrareader and interreader
ariability.
uclear cardiology. The ASNC supports mandatory ac-
reditation of laboratories and mandatory certification of
hysicians practicing nuclear cardiology by January 1, 2008;
ew laboratories should be allowed 2 years to become
ccredited (12). Laboratories can be accredited via Interso-
ietal Commission for Accreditation of Nuclear Laborato-
ies (36); the ACR also mandates accreditation and provides
n accreditation program (10). Physician certification can be
btained via the Certification Board of Nuclear Cardiology,
nd physician readers should have at least COCATS level II
raining (37). Appropriateness criteria for SPECT imaging
ave been published (17). The working group recom-
ended that an instrument for measuring the appropriate-
ess of individual procedures be developed and piloted in
he near future. The first step is to ascertain the key
lements needed to measure and assess the frequency of
omplete data. The percentage of interpretable studies
hould be determined in each laboratory, with a focus on
orrective actions within a continuous quality improvement
lan. Intrareader and interreader variability should be eval-
ated by review of a standard set of studies, either internal
r Internet-based. The elements for structured reporting
ave been defined (31); quality metrics examining the
ompleteness and definitiveness of reports are under devel-
pment. The timeliness of reporting is critical, and time-
ines will be established and monitored for compliance. The
mpact of SPECT imaging may be assessed by the fre-
uency with which patients with abnormal SPECT exam-
nations referred for angiography are subsequently found to
ave normal coronary arteries.
ardiac CT. Training guidelines were recently published
or cardiac CT by the ACC (23,38) and ACR (24).
aboratory accreditation is under development by the Inter-
ocietal Commission and the ACR. The ACC Foundation
lso published appropriateness criteria for cardiac CT in
006 (39). The development of standard protocols such as
ose modulation is critical. Radiation dosimetry and con-
rast usage are suggested metrics to monitor safety. It was
uggested that the lesser of 5% of studies or 50 studies be
ver-read annually to assess interpretative variability, and
hat accuracy be directly evaluated by comparison with
nvasive coronary angiography. Standard reporting data
lements will soon be identified, with a movement toward a
tandardized report. As measures of outcome, impact on
atheterization laboratory referrals and false-positive CT
ngiogram rates may serve as initial quality metrics.
ardiovascular MR. The Society for Cardiovascular Mag-
etic Resonance is working to provide a mechanism for
ccreditation under the Intersocietal Accreditation Com- sission umbrella. The ACR will also offer accreditation for
ardiac MR imaging by early 2007. Established training
equirements for the performance and interpretation of
MR studies published by the ACC and ACR (24,40,41)
an ensure interpreter proficiency. The ACC Foundation
as published appropriateness criteria for CMR (39), and
ethods for the evaluation of patient selection will follow,
uch as the frequency of an appropriate indication being
ncluded on an ordering form. The Society for Cardiovas-
ular Magnetic Resonance will create standard scan proto-
ols and publish imaging guidelines. Evaluation of in-
rareader and interreader variability and correlation with
ther modalities should be implemented and reviewed in
ach laboratory on a regular basis. Interreader variability
ssessments may require collaboration among multiple cen-
ers or the use of an Internet-based standard image set.
eporting standards are yet to be established, but key data
lements will soon be identified. As potential initial out-
ome measures, patient and referring physician satisfaction
hould be evaluated.
iagnostic angiography. A review of an invasive angiog-
aphy laboratory is usually included within hospital accred-
tation by organizations such as JCAHO. Efforts are under-
ay to develop appropriateness criteria for the use of
iagnostic coronary angiography. Patient radiation exposure
ither by fluoroscopic time or dose area product should be
racked for all cases (42), because radiation skin injury is a
CAHO-reviewable sentinel event. As an additional mea-
ure of safety, contrast volume, complications, and risk-
djusted mortality should be assessed. Radiation exposure
onitoring and annual radiation safety education should be
rovided to all employees involved with ionizing radiation
42). The working group discussed the importance of image
cquisition quality assessment and dosimetry techniques
uch as the National Electrical Manufacturers Association
ociety for Cardiovascular Angiography and Interventions
R-21 phantom (20). Although considered essential, using
standardized phantom was not a formal recommendation
t this time. Intrareader and interreader variability may be
ssessed through conferences or by review of standard
mages. Reporting of results should include key data that are
ubsequently incorporated into a standardized report. The
orking group is developing an outline of key elements for
he catheterization report to assist the individual labora-
ory. Finally, the working group recommended partici-
ation in registry programs, such as the ACC National
ardiovascular Data Registry and use of quality improve-
ent tools, such as ACC-CathKit, to provide valuable
eference data regarding quality outcomes, including the
ate of normal angiograms.
MPLEMENTATION ISSUES
chieving quality in cardiovascular imaging requires the
ustained, coordinated efforts of many stakeholders. Profes-
ional organizations can play a pivotal role by defining what
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tandards and quality measures, and supplementing existing
tandards and guidelines. They must also convince their
embers of the benefits of participating in quality improve-
ent initiatives and develop the tools to facilitate provider
nvolvement. Subspecialty societies are encouraged to continue
o establish committees whose focus is quality improvement
nd should form coalitions that can commit resources to
upporting data collection, analysis, and reporting.
The Cardiovascular Imaging Collaborative of the ACC
nd cardiovascular imaging societies can coordinate profes-
ional society efforts and liaise with other groups such as
ayers. Its membership should be expanded to interested
ayers, regulators, credentialing/accreditation bodies, and
uality experts. Both private and government payers must
ook beyond cost control and actively support quality initi-
tives. The Medical Directors’ Institute, an ACC-led con-
ortium of payers and physicians, has already identified
ardiovascular imaging as a high priority and can establish
ormal lines of communication. The Cardiovascular Imag-
ng Collaborative and ACC have also partnered with
ntegrating the Healthcare Enterprise (www.acc.org/ihe.
tm) to provide a mechanism for promoting uniform data
eporting and structured report formats for each modality,
s well as connectivity and cross-domain document sharing
mong vendors across health information systems.
Approval and support from the provider community is
ssential. Although there may be reluctance from providers
lready encumbered with reporting requirements, history
uggests that many are committed to quality improvement.
onetheless, the initial approach must encourage participa-
ion and reward demonstrated quality and/or quality im-
rovement.
Collecting even the simplest measures requires expertise,
ime, and money, even if the data collection is limited to an
n-site local process. External and internal reviews carry
dditional costs for data transmission and review, particu-
arly if a core laboratory or expert panel is involved.
nformation systems that incorporate quality assurance
ools, such as proper ordering information, standardized
eporting, and database construction, are also costly. How-
ver, we must invest in the processes and procedures that
ill improve cardiovascular care.
Concerns regarding the handling of medical errors de-
ected in the quality assessment process are relevant. This
rocess is driven by our desire to optimize patient care and
reate a mechanism for correcting errors without exposing a
rovider participant to liability. National efforts directed at
educing medication errors can be models (43).
ESEARCH ISSUES
raditionally, imaging research has focused on pathological
r physiological correlations, often with methodological
imitations (44). Much less is known about the application
f imaging in practice, including variability in patient geferrals, imaging acquisition, interpretation, and reporting.
here is a paucity of research on the incremental benefits of
maging in medical decision making and few rigorous
omparisons of different diagnostic strategies on meaningful
atient outcomes. Thus, existing guidelines are largely not
vidence based, but rather formed by expert consensus,
hich limits the development of valid quality measures (45).
Future research must expand beyond the traditional
arrow focus on technology and test characteristics of
ndividual modalities (Table 4). First, we need to under-
tand how quality is currently measured and what are the
est methods to ensure their continued effectiveness. Sec-
nd, identifying specific gaps in care will be necessary to
dentify targets for quality improvement research. Third,
omparisons of the benefits of different imaging strategies
ust be conducted in representative populations to identify
ptimal approaches to diagnosis in clinical practice. Fourth,
omprehensive validation of evidence-based quality mea-
ures should be performed that assesses both the benefits
nd unintended consequences. Finally, future studies should
nclude explicit considerations of cost.
Ideally, the benefits of new cardiovascular imaging tech-
ologies should be proven in rigorous randomized trials, but
any important questions may not be amenable to the
raditional clinical trials for ethical, cost, or feasibility
easons. In these cases innovative investigative approaches
hould be considered, such as the use of imaging registries
hat incorporate test indications, results of imaging, subse-
uent patient treatments, and health outcomes. Decision
nalysis also may be a useful approach for comparing the
enefits, risks, and costs of different imaging strategies (46).
Regardless of the methods used, generating the data
eeded to optimize the use of cardiovascular imaging will
equire substantial resources. Because a natural alignment
xists between the goals of practitioners, imaging quality
esearchers, and payers of healthcare services (whose bud-
able 4. Research Agenda for Assessing Quality in
ardiovascular Imaging
Evaluate current quality measurement programs and strategies for
maintaining high performance and continuous improvement in
cardiovascular imaging.
Identify important quality gaps in cardiovascular imaging.
Compare different cardiovascular imaging strategies and their impacts on
clinical practice and outcomes.
Create evidence-based methods to validate new cardiovascular imaging
quality measures.
Develop new clinical evidence when there is an absence of data that link
appropriateness of cardiovascular imaging with improved patient
outcomes.
Assess the benefits and unintended consequences of quality measurement
of cardiovascular imaging.
Investigate feasibility of randomized clinical trials, registries, and
decision-analytic models within cardiovascular imaging.
Conduct cost-effective analyses of cardiovascular imaging strategies and
potential methods of collaboration between payers and providers.ets for cardiovascular imaging have increased exponen-
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ONCLUSIONS
he ACC–Duke quality in imaging meeting was an ex-
raordinary collaboration of stakeholders in cardiovascular
maging that accomplished multiple important steps leading
o improved quality. The consensus development of the
imensions of care framework for assessing quality identi-
ed common themes and concerns that lay the foundation
or subsequent work for each imaging modality. It is hoped
hat each subspecialty society and its members will commit
o move rapidly from theoretical discussions to the creation
nd implementation of specific measures. We anticipate an
nnual series of stakeholder meetings to encourage efforts,
easure progress, and ensure coordination.
Strong leadership is needed to accomplish these perhaps
ostly, perhaps difficult, but necessary undertakings. To be
uccessful, this effort will require commitments from a broad
ange of practitioners, payers, and policymakers. Commit-
ed individuals should work with the ACC, cardiovascular
maging societies, payers, and industry to continue to
evelop the tools and processes described. Each laboratory
hould embrace continuous quality improvement and im-
lement agreed-on measures to achieve a high level of
erformance. It is a professional mandate for all stakehold-
rs to ensure that cardiovascular imaging is subject to the
ame quality considerations as more invasive or potentially
irectly harmful treatments.
eprint requests and correspondence: Dr. Pamela S. Douglas,
uke University Medical Center 3943, Duke North 7451,
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